Which laboratory result may indicate an adverse effect in a client taking tacrolimus?

Tacrolimus is an immunosuppressive medication commonly used to prevent organ transplant rejection and treat certain autoimmune diseases. One of the known adverse effects of tacrolimus is the potential for it to induce hyperglycemia, or elevated blood glucose levels.

A fasting blood glucose level of 200 mg/dL indicates hyperglycemia, which is a significant concern because it suggests that the client's body may not be regulating blood sugar levels properly. This can lead to further complications, including the development of diabetes, especially in patients taking medications like tacrolimus that can affect glucose metabolism.

The other laboratory results provided do not specifically relate to common adverse effects associated with tacrolimus therapy. A hematocrit of 33% might suggest anemia but is not directly linked as a typical adverse effect of tacrolimus. A white blood cell count of 8,000/mm³ falls within the normal range and shows no sign of myelosuppression, which is another potential risk of immunosuppressive drugs. Lastly, a creatinine level of 1.2 mg/dL is also within an acceptable range for renal function and does not indicate renal impairment, which could be a concern with tacrolimus use.

In summary, the elevated fasting blood glucose